V. Fantin

Molecular Biology · 2006–2010

A researcher in the Science corpus: 5 papers; trusts 2 researchers and is trusted by 10 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 23 citations into it; #5,244 of 17,773 by trust here, #3,681 by citations
• Cancer Research — 15 citations into it; #286 of 1,780 by trust here, #231 by citations

Whom V. Fantin trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Robert A. Gatenby
2. Robert James Gillies

Who trusts V. Fantin overall

1. M. V. Vander Heiden
2. C. V. Dang
3. Ralph J. Deberardinis
4. Simone Fulda
5. D. Trachootham
6. Karen H. Vousden
7. Jie Zheng
8. G. Brooks
9. L. Galluzzi
10. Guido Kroemer

Papers from V. Fantin's perspective

Ordered by how strongly the researchers V. Fantin trusts endorse each paper. Same corpus, a different order for every researcher.

1. IDH1 and IDH2 mutations in gliomas. (New England Journal of Medicine)
2. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (Nature)
3. The PyMOL Molecular Graphics System
4. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy (Nature Biotechnology)
5. Analysis of the IDH1 codon 132 mutation in brain tumors (Acta Neuropathologica)
6. IDH1 and IDH2 Mutations in Gliomas (New England Journal of Medicine)
7. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis (Proceedings of the National Academy of Sciences of the United States of America)
8. Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α (Science)
9. Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome (New England Journal of Medicine)
10. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. (Journal of Clinical Oncology)

Their papers

• Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. (2006) — 1,658 citations
• Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation (2010) — 2,704 citations
• Cancer-associated IDH1 mutations produce 2-hydroxyglutarate (2009) — 4,048 citations
• The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate (2010) — 1,965 citations
• Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations (2010) — 740 citations